GLP-1 Drugs Associated with 74% Lower Alcohol Addiction Risk in Largest Study Yet
Ozempic, Wegovy, and related GLP-1 drugs are already known for transforming diabetes care and obesity treatment. But a growing body of evidence suggests these medications influence far more than blood sugar and appetite. The largest study yet to examine the connection, published in Frontiers in Psychiatry, found that patients taking GLP-1 receptor agonists had dramatically lower rates of substance use disorders across alcohol, opioids, nicotine, and cocaine.
The findings add to a rapidly expanding picture of GLP-1 drugs as modulators of brain reward circuitry — a mechanism that could reshape how addiction is treated.
The numbers
Researchers at the University of Texas at El Paso analyzed data from 142,349 participants in the National Institutes of Health’s All of Us Research Program, a nationally representative longitudinal health database. Using a nested case-control design, they matched GLP-1 users with non-users on age, sex, race, ethnicity, and diabetes or obesity status.
The results were striking. After propensity score matching, GLP-1 use was associated with:
- 74% lower odds of alcohol use disorder (OR 0.26, 95% CI 0.20-0.34, p=0.0001)
- 69% lower odds of opioid use disorder (OR 0.31, 95% CI 0.23-0.42, p=0.0001)
- 68% lower odds of nicotine use disorder (OR 0.32, 95% CI 0.27-0.39, p=0.001)
- 75% lower odds of cocaine use disorder (OR 0.25, 95% CI 0.16-0.40, p=0.0001)
Overall, GLP-1 use was associated with 75% lower odds of any substance use disorder.
The analysis included four GLP-1 receptor agonists: liraglutide, semaglutide, exenatide, and dulaglutide. To reduce reverse causality — the possibility that people already in recovery were more likely to be prescribed GLP-1s — the researchers required that the prescription fill occurred at least 90 days before the index date.
How GLP-1 drugs affect the brain
GLP-1 receptors are not limited to the pancreas and gut. They are expressed in brain regions central to reward and reinforcement, particularly the ventral tegmental area (VTA) and the nucleus accumbens — the same circuitry targeted by addictive substances.
When a GLP-1 receptor agonist binds to these receptors, it attenuates dopamine release in the reward pathway. This dampens the reinforcing effect of drugs and alcohol, reducing cravings and compulsive seeking behavior. Animal studies have shown that liraglutide at 0.1 mg/kg significantly reduces voluntary alcohol consumption in rats, consistent with the human findings.
The pathway may extend beyond dopamine modulation. GLP-1 signaling also suppresses neuroinflammation and attenuates stress-related neural circuits, both of which are implicated in addiction relapse.
Caveats: observational, not causal
The study has important limitations that its authors are careful to acknowledge. This is a retrospective observational study, not a randomized controlled trial. The association between GLP-1 use and lower addiction rates does not prove causation.
“We do not support prescribing these medications for addiction treatment at this time,” said Gabriel Frietze, a co-author at UT El Paso. “Because this was an observational study in a specific clinical population, randomized clinical trials are needed before GLP-1 medications can be recommended for treating addiction.”
The study population was also restricted to individuals with type 2 diabetes or obesity — the populations for whom GLP-1 drugs are currently approved. Whether similar effects would be seen in people without these conditions is unknown.
Additional limitations include the reliance on prescription records rather than confirmed medication adherence, and the possibility of residual confounding despite propensity score matching. The study’s lead author, Tadesse M. Abegaz, noted that diagnosis dates in medical records may not reflect true symptom onset for substance use disorders.
The bigger picture
The UT El Paso study joins a fast-growing literature on the neurological effects of GLP-1 receptor agonists. Separate research has found associations between GLP-1 use and lower rates of Alzheimer’s disease, Parkinson’s disease, and depression — hinting at a broad neuroprotective role for these drugs.
Several randomized clinical trials are now underway to test GLP-1 agonists directly for addiction treatment. If they confirm the observational findings, it would represent a paradigm shift: a class of drugs already taken by millions for diabetes and weight loss, sitting on pharmacy shelves, that could be deployed against the addiction crisis.
For now, the message from the researchers is measured. “Our findings add to growing evidence that GLP-1 medications may influence more than appetite and blood sugar regulation,” Abegaz said. “These medications appear to affect brain pathways involved in reward and craving.” Whether that translates into a new treatment for addiction awaits the gold standard of clinical trials.
Source
Abegaz TM, Ahmed M, Bhagavathula AS, Frietze G. Association between GLP-1 receptor agonist use and substance use disorders among individuals with type 2 diabetes or obesity: a nested case-control study in the All of Us research program. Frontiers in Psychiatry. 2026;17:1766770. DOI: 10.3389/fpsyt.2026.1766770